	US 12,152,253 B2
	Natural killer cells with enhanced immune response
Sungjin Kim, Davis, CA (US); and Jeannine Scott, Charlotte, MI (US)
Assigned to Board of Trustees of Michigan State University, East Lansing, MI (US)
Filed by Board of Trustees of Michigan State University, East Lansing, MI (US)
Filed on Jul. 25, 2018, as Appl. No. 16/044,866.
Application 16/044,866 is a division of application No. 13/865,762, filed on Apr. 18, 2013, granted, now 10,066,207.
Claims priority of provisional application 61/625,725, filed on Apr. 18, 2012.
Prior Publication US 2019/0010457 A1, Jan. 10, 2019
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01); C12N 5/0783 (2010.01); A61K 39/395 (2006.01)

CPC C12N 5/0646 (2013.01) [A61K 35/17 (2013.01); Y02A 50/30 (2018.01)]

15 Claims

1. A composition comprising a cell population comprising natural killer (NK) cells that express CD16 and do not express detectable FcRγ (g-NK cells) and at least one physiologically acceptable carrier, wherein at least 50% of the cells in the composition are g-NK cells and wherein the composition comprises a therapeutically effective amount of 10⁶to 10¹²g-NK cells, wherein the composition is frozen to preserve the cells.